National Health Determination under paragraph 98C(1)(b) Amendment 2017 (No. 7) (PB 86 of 2017) (Cth)

PB 86 of 2017

National Health Determination under paragraph 98C(1)(b) Amendment 2017
(No. 7)

_____________________________________________________________________

I, LISA LA RANCE, Assistant Secretary, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under paragraph 98C(1)(b) of the National Health Act 1953.

Dated         20^th October 2017

LISA LA RANCE

Assistant Secretary

Pricing and Policy Branch

Technology Assessment and Access Division

Department of Health

1              Name of Instrument

(1)This Instrument is the National Health Determination under paragraph 98C(1)(b) Amendment 2017 (No. 7).

(2)This Instrument may also be cited as PB 86 of 2017.

2              Commencement  

This instrument commences on 1 November 2017.

3              Amendments to Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008)

Schedule 1 amends the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008).

Schedule 1            Amendments

1. Schedule 1, after entry for Cefuroxime with Water ─ Purified BP in the form Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL

insert in the column headed “Form (strength, type, size, etc.)”:

Powder for oral suspension 125 mg (as axetil) per 5 mL, 100 mL

1. Schedule 4, after entry for Cefuroxime in the form Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL

insert in the column headed “Form (strength, type, size, etc.)”:

Powder for oral suspension 125 mg (as axetil) per 5 mL, 100 mL